Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Open access
Carreira, Suzanne, Porta, Nuria, Arce-Gallego, Sara, Seed, George, Llop-Guevara, Alba, Bianchini, Diletta, Rescigno, Pasquale, Paschalis, Alec, Bertan, Claudia, Baker, Chloe, Goodall, Jane, Miranda, Susana, Riisnaes, Ruth, Figueiredo, Ines, Ferreira, Ana, Pereira, Rita, Crespo, Mateus, Gurel, Bora, Nava Rodrigues, Daniel, Pettitt, Stephen J., Yuan, Wei, Serra, Violeta, Rekowski, Jan, Lord, Christopher J., Hall, Emma, Mateo, Joaquin, de Bono, Johann S. · 2021 · Cancer Discovery

Abstract

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass whole-genome sequencing and IHC and IF assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA2 deletion. Biallelic, but not monoallelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by IHC was associated with a better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alterations while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM IHC expression associated with clinical benefit. Significance: Not all APCs with DNA repair defects derive similar benefit from PARP inhibition. Most benefit was seen among patients with BRCA2 homozygous deletions, biallelic loss of PALB2, and loss of ATM protein. Loss of RAD51 foci, evaluating homologous recombination repair function, was found primarily in tumors with biallelic BRCA1/2 and PALB2 alterations. This article is highlighted in the In This Issue feature, p. 2659

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0007

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 159

Metadata

Authors
Carreira, S., Porta, N., Arce-Gallego, S., Seed, G., Llop-Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C., Baker, C., Goodall, J., Miranda, S., Riisnaes, R., Figueiredo, I., Ferreira, A., Pereira, R., Crespo, M., Gurel, B., Nava Rodrigues, D., Pettitt, S. J., Yuan, W., Serra, V., Rekowski, J., Lord, C. J., Hall, E., Mateo, J., & de Bono, J. S.
Venue
Cancer Discovery
Published
2021-05-27
Volume
11
Issue
11
Pages
2812-2827
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3165176963
Cited by
159
References
11
FWCI
10.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0007
The paper
Carreira, S., Porta, N., Arce-Gallego, S., Seed, G., Llop-Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C., Baker, C., Goodall, J., Miranda, S., Riisnaes, R., Figueiredo, I., Ferreira, A., Pereira, R., Crespo, M., Gurel, B., Nava Rodrigues, D., . . . de Bono, J. S. (2021). Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.